Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
The pharmaceutical sector is continuously evolving, with several key patents set to expire in the coming years. To ensure the development of next-generation treatments, companies must stay abreast of the
Poolbeg Pharma plc (LON:POLB) investor presentation with CEO Jeremy Skillington. In this presentation Jeremy covers: Company Overview and Strategic PositionIntroduction to Poolbeg Pharma and its strategic positioning in the industry.Overview of
New research published in the journal Drug Discovery Today reveals that drugs discovered through artificial intelligence (AI) have a significantly higher success rate in Phase I clinical trials (80-90%) compared
Poolbeg Pharma plc (LON: POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has confirmed that the Company’s Annual Report
Poolbeg Pharma said it had made progress last year in expanding its treatments into new markets, with significant pipeline advancements and strategic deals. The company said it had made a
Poolbeg Pharma announced significant advances and strategic expansions in its latest financial year, most notably with POLB 001 targeting a market opportunity exceeding $10 billion in cancer immunotherapy-induced Cytokine Release
Poolbeg Pharma plc (LON:POLB, OTCQB:POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that, further to its announcement on 20 March 2024, the
Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has entered
Poolbeg Pharma plc (LON:POLB, OTCQB:POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
